Standigm Raises US $11.5 Million in Series B Round Funding to Advance Its AI-Powered Drug Pipelines Toward License-Out
Standigm, an AI-powered drug discovery company, has raised $11.5 million in a Series B funding round. The funds will be used to scale the AI technology platforms and advance its drug discovery pipelines for untreatable diseases. - March 29, 2019
Standigm Launches Artificial Intelligence-Driven Drug Discovery Service at 2019 BIO-Asia International Conference in Tokyo, Japan
Standigm, a company using the advanced AI technology to drug discovery, launched the customized early drug discovery and target study service, "Standigm Insight®," at 2019 BIO-Asia International Conference in Tokyo, Japan. Standigm Insight® provides AI-driven new indication prediction and novel target analysis service for customer’s in-house products. - March 04, 2019
Standigm Launches Artificial Intelligence-Driven Lead Optimization Service at BIO-Europe 2018 in Copenhagen, Denmark
Standigm, a company using the advanced AI technology to drug discovery, launched the customized lead optimization service, "Standigm BEST®," at BIO-Europe 2018 in Copenhagen, Denmark. Standigm BEST® provides AI-driven lead optimization and can also be utilized for fast-follow hit identification or patent fencing strategy. One-to-one meetings have been scheduled with leading pharmaceutical companies, indicating their interest in Standigm BEST®. - November 05, 2018